Food Additive alpha GPC (Choline glycerophosphate)cas CAS 28319-77-9 99% powder

Food Additive alpha GPC (Choline glycerophosphate)cas CAS 28319-77-9 99% powder

Min.Order / FOB Price:Get Latest Price

1 Kilogram	FOB Price: USD 1.0000

1 Kilogram

FOB Price: USD 1.0000

Min.Order :1 Kilogram
Purity: 99%
Payment Terms : L/C,T/T

Keywords

Choline glycerophosphate alpha GPC SN-GLYCEROPHOSPHORYLCHOLINE (EGG)

Quick Details

Appearance:White Fine Powder
Application:1. Potent Acetylcholine Source; 2. Improved Memory; 3. Improve mental focus and cognitive function; 4. Advanced Learning; 5. Brain Antioxidant.
PackAge:1KG, 25 KG drum
ProductionCapacity:10|Metric Ton|Month
Storage:Please store in cool, dry and ventilation place
Transportation:Safe shipping by sea EMS FEDEX DHL

Superiority:

L-Alpha Glycerylphosphorylcholine (Alpha GPC, choline alfoscerate) 28319-77-9 is a natural choline compound found in the brain and in milk. It is also a parasympathomimetic acetylcholine precursor which may have potential for the treatment of Alzheimer's disease and is used as a nootropic dietary supplement to enhance memory and cognition.

The main benefit to Alpha GPC is its noticeable nootropic qualities. It is used as a prescription medication and has merit in treating many mental deficiencies. Alpha GPC has qualities of treating overall general mental health including learning and memory, thinking skills and mood.

Several studies have shown Alpha GPC to be beneficial for depression and mood. Lacking in choline can lead to depression and low energy levels. Supplementation of Alpha GPC can have great benefits for these individuals.

Details:

Alpha GPC rapidly delivers choline to the brain across the blood–brain barrier and is a biosynthetic precursor of the acetylcholine neurotransmitter.Alpha GPC is derived from highly purified soy lecithin by companies like Lipoid, VAV Life Sciences, Chemi SPA etc.

Studies have investigated its efficacy for cognitive disorders including stroke and Alzheimer’s Disease. An Italian multicentre clinical trial on 2,044 patients suffering from recent stroke were supplied alpha-GPC in doses of 1,000 mg/day for 28 days and 400 mg three times per day for the five ensuing months. The trial confirmed the therapeutic role of alpha-GPC on the cognitive recovery of patients based on four measurement scales, three of which reached statistical significance.

View All